Lisa Cook sues Trump over firing attempt, emergency hearing set
Investing.com - Stifel lowered its price target on Revvity Inc (NYSE:RVTY) to $110.00 from $120.00 on Tuesday, while maintaining a Hold rating on the stock. The company, currently trading at $95.73, maintains strong fundamentals with a perfect Piotroski Score of 9, according to InvestingPro data.
The price target reduction follows Revvity’s second-quarter results, which Stifel noted were largely in line with expectations across most business segments.
The firm highlighted that certain product categories outperformed, specifically mentioning Revvity’s Signals software, which continued to demonstrate robust growth of approximately 30% during the quarter.
Despite these positive areas, Stifel pointed to new pressures in China for Revvity’s ImmunoDx business, citing DRG-driven reimbursement changes that have caused growth to step down and impacted the company’s overall outlook for the year.
Stifel expressed concern about these fluid dynamics in the Chinese diagnostics market, noting they are particularly significant for Revvity as many investors had gravitated toward the stock because the diagnostics business appeared to offer a safe harbor from academic and biopharma concerns affecting most of the core Tools group.
In other recent news, Revvity Inc. reported its second-quarter 2025 earnings, surpassing analyst expectations with an adjusted earnings per share of $1.18, compared to the forecasted $1.14. The company’s revenue also exceeded expectations, reaching $720 million against an anticipated $710.39 million. Despite these positive earnings results, several analyst firms have adjusted their price targets for Revvity due to external challenges. Raymond (NSE:RYMD) James lowered its price target to $115, citing reimbursement headwinds in China affecting the growth of multiplex immunodiagnostics. Similarly, Bernstein SocGen Group reduced its price target to $115, maintaining a Market Perform rating, noting the alignment of organic growth with consensus estimates. Jefferies also lowered its target to $100, highlighting concerns over China’s drug-related group policies impacting Revvity’s financial outlook. These developments reflect the cautious stance analysts are taking despite the company’s earnings beat.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.